Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14995052 | 1.00 | CCR4 (0.42) | CCR4KHK | |
| SCHEMBL14995051 | 1.00 | CCR4 (0.42) | CCR4KHK | |
| SCHEMBL27978187 | 0.89 | CCR4 (0.39) | CCR4 | |
| SCHEMBL27978183 | 0.89 | CCR4 (0.39) | CCR4 | |
| SCHEMBL14994962 | 0.89 | SOS1 (0.41) | CCR4 | |
| SCHEMBL15053400 | 0.89 | SOS1 (0.41) | CCR4 | |
| SCHEMBL15692597 | 0.89 | CCR4 (0.42) | CCR4 | |
| SCHEMBL27978185 | 0.89 | SOS1 (0.41) | CCR4 | |
| SCHEMBL15053683 | 0.87 | SOS1 (0.48) | CCR4 | |
| SCHEMBL15053684 | 0.87 | SOS1 (0.48) | CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647696-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CHEMOCENTRYX, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180127395-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-05-10 | — | — | US | disclosed |
| CN-103974950-A | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CHEMOCENTRYX INC | 2014-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127395-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | CCR4 1/4885KHK 2687/4885 |
| US-10647696-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CCR4, CCR1, CCR3 | CCR4 1/4885KHK 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.